1. Dinarello, CA (2004) Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Current Opinion in Pharmacology 4: 378–385. DOI: 10.1016/j.coph.2004.03.010.
Google Scholar | Crossref | Medline | ISI2. Rondeau, JM, Ramage, P, Zurini, M, et al. (2015) The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β. MAbs 7: 1151–1160. DOI: 10.1080/19420862.2015.1081323.
Google Scholar | Crossref | Medline3. Hoy, SM (2015) Canakinumab: a review of its use in the management of systemic juvenile idiopathic arthritis. BioDrugs 29: 133–142. DOI: 10.1007/s40259-015-0123-8.
Google Scholar | Crossref | Medline4. Wulffraat, NM (2015) A safety evaluation of canakinumab for the treatment of systemic onset juvenile idiopathic arthritis. Expert Opinion on Drug Safety 14: 1961–1967. DOI: 10.1517/14740338.2016.1112377.
Google Scholar | Crossref | Medline5. Ridker, PM, Howard, CP, Walter, V, et al. (2012) Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 126: 2739–2748. DOI: 10.1161/CIRCULATIONAHA.112.122556.
Google Scholar | Crossref | Medline | ISI6. Zangrillo, A, Beretta, L, Scandroglio, AM, et al. (2020) Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in Milan, Italy. Critical Care Resuscitation 22: 200–211.
Google Scholar | Medline7. Zhou, F, Yu, T, Du, R, et al. (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395: 1054–1062. DOI: 10.1016/S0140-6736(20)30566-3.
Google Scholar | Crossref | Medline8. Characterisation WHOWGotC and Management of C-i (2020) A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases 20: e192–e197. DOI: 10.1016/S1473-3099(20)30483-7.
Google Scholar | Crossref | Medline9. Lee, DW, Gardner, R, Porter, DL, et al. (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124: 188–195. DOI: 10.1182/blood-2014-05-552729.
Google Scholar | Crossref | Medline | ISI10. Lee, DW, Santomasso, BD, Locke, FL, et al. (2019) ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biology of Blood and Marrow Transplantation 25: 625–638. DOI: 10.1016/j.bbmt.2018.12.758.
Google Scholar | Crossref | Medline11. Duca, A, Piva, S, Foca, E, et al. (2020) Calculated decisions: Brescia-COVID respiratory severity scale (BCRSS)/algorithm. Emergency Medicine Practice 22: CD1–CD2.
Google Scholar | Medline12. Yin, X, Min, X, Nan, Y, et al. (2020) Assessment of the severity of coronavirus disease: quantitative computed tomography parameters versus semiquantitative visual score. Korean Journal of Radiology 21: 998–1006. DOI: 10.3348/kjr.2020.0423.
Google Scholar | Crossref | Medline13. Liu, F, Li, L, Xu, M, et al. (2020) Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. Journal of Clinical Virology 127: 104370. DOI: 10.1016/j.jcv.2020.104370.
Google Scholar | Crossref | Medline14. Wang, L (2020) C-reactive protein levels in the early stage of COVID-19. Médecine et Maladies Infectieuses 50: 332–334. DOI: 10.1016/j.medmal.2020.03.007.
Google Scholar | Crossref | Medline15. Wang, D, Hu, B, Hu, C, et al. (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323: 1061–1069. DOI: 10.1001/jama.2020.1585.
Google Scholar | Crossref | Medline16. Ye, Q, Wang, B, Mao, J (2020) The pathogenesis and treatment of the `Cytokine Storm’ in COVID-19. Journal of Infection 80: 607–613. DOI: 10.1016/j.jinf.2020.03.037.
Google Scholar | Crossref | Medline17. Qin, C, Zhou, L, Hu, Z, et al. (2020) Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clinical Infectious Diseases 71: 762–768. DOI: 10.1093/cid/ciaa248.
Google Scholar | Crossref | Medline18. Coomes, EA, Haghbayan, H (2020) Interleukin-6 in Covid-19: A systematic review and meta-analysis. Reviews Medical Virology 30(6): 1–9. DOI: 10.1002/rmv.2141.
Google Scholar | Crossref | Medline19. Ucciferri, C, Auricchio, A, Di Nicola, M, et al. (2020) Canakinumab in a subgroup of patients with COVID-19. Lancet Rheumatology 2: e457–ee458. DOI: 10.1016/s2665-9913(20)30167-3.
Google Scholar | Crossref | Medline20. Sheng, CC, Sahoo, D, Dugar, S, et al. (2020) Canakinumab to reduce deterioration of cardiac and respiratory function in SARS-CoV-2 associated myocardial injury with heightened inflammation (canakinumab in Covid-19 cardiac injury: The three C study). Clinical Cardiology 43: 1055–1063. DOI: 10.1002/clc.23451.
Google Scholar | Crossref | Medline